Market open

NeoGenomics/$NEO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About NeoGenomics

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Ticker

$NEO
Trading on

Industry

Health Care Providers & Services

Employees

2,200

NeoGenomics Metrics

BasicAdvanced
$1.2B
-
-$0.62
1.23
-
$1.2B
1.23
$19.12
$8.98
1.3M
1.979
1.784
44.46
67.085
-10.83%
-3.22%
-8.54%
1.825
1.35
30.58
-35.425
11.65%
-11.32%
10.90%
107.08%

What the Analysts think about NeoGenomics

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for NeoGenomics stock.

NeoGenomics Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

NeoGenomics Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NEO

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs

What’s the current market cap for NeoGenomics stock?

NeoGenomics (NEO) has a market cap of $1.2B as of March 14, 2025.

What is the P/E ratio for NeoGenomics stock?

The price to earnings (P/E) ratio for NeoGenomics (NEO) stock is 0 as of March 14, 2025.

Does NeoGenomics stock pay dividends?

No, NeoGenomics (NEO) stock does not pay dividends to its shareholders as of March 14, 2025.

When is the next NeoGenomics dividend payment date?

NeoGenomics (NEO) stock does not pay dividends to its shareholders.

What is the beta indicator for NeoGenomics?

NeoGenomics (NEO) has a beta rating of 1.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.